Page 1341 - Williams Hematology ( PDFDrive )

1316 Part X: Malignant Myeloid Diseases Chapter 85: Essential Thrombocythemia 1317

7. Landgren O, Goldin LR, Kristinsson SY, et al: Increased risks of polycythemia vera, 40. Wolanskyj AP, Schwager SM, McClure RF, et al: Essential thrombocythemia beyond
essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of the first decade: Life expectancy, long-term complication rates, and prognostic factors.
11,039 patients with myeloproliferative neoplasms in Sweden. Blood 112:2199, 2008. Mayo Clin Proc 81:159, 2006.
8. Cross NCP: Genetic and epigenetic complexity in myeloproliferative neoplasms. Hema- 41. Wilkins BS, Erber WN, Bareford D, et al: Bone marrow pathology in essential throm-
tology Am Soc Hematol Educ Program 2011:208, 2011. bocythemia: Interobserver reliability and utility for identifying disease subtypes. Blood
9. Levine RL, Pardanani A, Tefferi A, Gilliland DG: Role of JAK2 in the pathogenesis and 111:60, 2008.
therapy of myeloproliferative disorders. Nat Rev Cancer 7:673, 2007. 42. Campbell PJ, Scott LM, Buck G, et al: Definition of subtypes of essential thrombocy-
10. Witthuhn BA, Quelle FW, Silvennoinen O, et al: JAK2 associates with the erythropoi- thaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: A
etin receptor and is tyrosine phosphorylated and activated following stimulation with prospective study. Lancet 366:1945, 2005.
erythropoietin. Cell 74:227, 1993. 43. Vannucchi AM, Antonioli E, Guglielmelli P, et al: Clinical correlates of JAK2V617F
11. Drachman JG, Millett KM, Kaushansky K: Thrombopoietin signal transduction presence or allele burden in myeloproliferative neoplasms: A critical reappraisal. Leu-
requires functional JAK2, not TYK2. J Biol Chem 274:13480, 1999. kemia 22:1299, 2008.
12. Parganas E, Wang D, Stravopodis D, et al: Jak2 is essential for signaling through a vari- 44. Rotunno G, Mannarelli C, Guglielmelli P, et al: Impact of calreticulin mutations on clin-
ety of cytokine receptors. Cell 93:385, 1998. ical and hematological phenotype and outcome in essential thrombocythemia. Blood
13. Remy I, Wilson IA, Michnick SW: Erythropoietin receptor activation by a ligand- 123:1552, 2014.
induced conformation change. Science 283:990, 1999. 45. Rumi E, Pietra D, Ferretti V, et al: JAK2 or CALR mutation status defines subtypes of
14. Brooks AJ, Dai W, O’Mara ML, et al: Mechanism of activation of protein kinase JAK2 by essential thrombocythemia with substantially different clinical course and outcomes.
the growth hormone receptor. Science 344:1249783, 2014. Blood 123:1544, 2014.
15. Bandaranayake RM, Ungureanu D, Shan Y, et al: Crystal structures of the JAK2 pseu- 46. Kiladjian JJ, Rain JD, Bernard JF, et al: Long-term incidence of hematological evolution
dokinase domain and the pathogenic mutant V617F. Nat Struct Mol Biol 19:754, 2012. in three French prospective studies of hydroxyurea and pipobroman in polycythemia
16. Li J, Kent DG, Chen E, Green AR: Mouse models of myeloproliferative neoplasms: JAK vera and essential thrombocythemia. Semin Thromb Hemost 32:417, 2006.
of all grades. Dis Model Mech 4:311, 2011. 47. Finazzi G, Caruso V, Marchioli R, et al: Acute leukemia in polycythemia vera: An analy-
17. Beer PA, Campbell PJ, Scott LM, et al: MPL mutations in myeloproliferative disorders: sis of 1638 patients enrolled in a prospective observational study. Blood 105:2664, 2005.
Analysis of the PT-1 cohort. Blood 112:141, 2008. 48. Berk PD, Goldberg JD, Silverstein MN, et al: Increased incidence of acute leukemia in
18. Vannucchi AM, Antonioli E, Guglielmelli P, et al: Characteristics and clinical correlates polycythemia vera associated with chlorambucil therapy. N Engl J Med 304:441, 1981.
of MPL 515W>L/K mutation in essential thrombocythemia. Blood 112:844, 2008. 49. Theocharides A, Boissinot M, Girodon F, et al: Leukemic blasts in transformed
19. Staerk J, Lacout C, Sato T, et al: An amphipathic motif at the transmembrane-cytoplasmic JAK2-V617F-positive myeloproliferative disorders are frequently negative for the
junction prevents autonomous activation of the thrombopoietin receptor. Blood 107: JAK2-V617F mutation. Blood 110:375, 2007.
1864, 2006. 50. Andersson PO, Ridell B, Wadenvik H, Kutti J: Leukemic transformation of essential
20. Ding J, Komatsu H, Iida S, et al: The Asn505 mutation of c-MPL gene, which causes thrombocythemia without previous cytoreductive treatment. Ann Hematol 79:40, 2000.
familial essential thrombocythemia, induces autonomous homodimerization of the 51. Bench AJ, White HE, Foroni L, et al: Molecular diagnosis of the myeloproliferative neo-
c-Mpl protein due to strong amino acid polarity. Blood 114:3325, 2009. plasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations.
21. Pikman Y, Lee BH, Mercher T, et al: MPLW515L is a novel somatic activating mutation Br J Haematol 160:25, 2013.
in myelofibrosis with myeloid metaplasia. PLoS Med 3:e270, 2006. 52. Griesshammer M, Bangerter M, Sauer T, et al: Aetiology and clinical significance of
22. Oh ST, Simonds EF, Jones C, et al: Novel mutations in the inhibitory adaptor protein thrombocytosis: Analysis of 732 patients with an elevated platelet count. J Intern Med
LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood 245:295, 1999.
116:988, 2010. 53. Buss DH, Cashell AW, O’Connor ML, et al: Occurrence, etiology, and clinical signifi-
23. Wang WA, Groenendyk J, Michalak M: Calreticulin signaling in health and disease. Int cance of extreme thrombocytosis: A study of 280 cases. Am J Med 96:247, 1994.
J Biochem Cell Biol 44:842, 2012. 54. Skoda R: The genetic basis of myeloproliferative disorders. Hematology Am Soc Hematol
24. Nangalia J, Massie CE, Baxter EJ, et al: Somatic CALR mutations in myeloproliferative Educ Program 2007:1, 2007.
neoplasms with nonmutated JAK2. N Engl J Med 369:2391, 2013. 55. Harrison CN, Gale RE, Wiestner AC, et al: The activating splice mutation in intron 3 of
25. Klampfl T, Gisslinger H, Harutyunyan AS, et al: Somatic mutations of calreticulin in the thrombopoietin gene is not found in patients with non-familial essential thrombo-
myeloproliferative neoplasms. N Engl J Med 369:2379, 2013. cythaemia. Br J Haematol 102:1341, 1998.
26. Rampal R, Al-Shahrour F, Abdel-Wahab O, et al: Integrated genomic analysis illustrates 56. Mead AJ, Rugless MJ, Jacobsen SE, Schuh A: Germline JAK2 mutation in a family with
the central role of JAK-STAT pathway activation in myeloproliferative neoplasm patho- hereditary thrombocytosis. N Engl J Med 366:967, 2012.
genesis. Blood 123:e123, 2014. 57. Marty C, Saint-Martin C, Pecquet C, et al: Germ-line JAK2 mutations in the kinase
27. Kim E, Abdel-Wahab O: Focus on the epigenome in the myeloproliferative neoplasms. domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and
Hematology Am Soc Hematol Educ Program 2013:538, 2013. HSP90 inhibitors. Blood 123:1372, 2014.
28. Dawson MA, Bannister AJ, Gottgens B, et al: JAK2 phosphorylates histone H3Y41 and 58. Beer PA, Erber WN, Campbell PJ, Green AR: How I treat essential thrombocythemia.
excludes HP1alpha from chromatin. Nature 461:819, 2009. Blood 117:1472, 2010.
29. Rinaldi CR, Rinaldi P, Alagia A, et al: Preferential nuclear accumulation of JAK2V617F 59. Campbell PJ, Bareford D, Erber WN, et al: Reticulin accumulation in essential throm-
in CD34+ but not in granulocytic, megakaryocytic, or erythroid cells of patients with bocythemia: Prognostic significance and relationship to therapy. J Clin Oncol 27:2991,
Philadelphia-negative myeloproliferative neoplasia. Blood 116:6023, 2010. 2009.
30. Harrison CN, Campbell PJ, Buck G, et al: Hydroxyurea compared with anagrelide in 60. Swerdlow SH, Campo E, Harris NL, et al: WHO Classification of Tumours of Haemato-
high-risk essential thrombocythemia. N Engl J Med 353:33, 2005. poietic and Lymphoid Tissues. IARC Press, Lyon, 2008.
31. Cortelazzo S, Finazzi G, Ruggeri M, et al: Hydroxyurea for patients with essential 61. Michiels JJ, Berneman Z, Schroyens W, et al: Philadelphia (Ph) chromosome-positive
thrombocythemia and a high risk of thrombosis. N Engl J Med 332:1132, 1995. thrombocythemia without features of chronic myeloid leukemia in peripheral blood:
32. Michiels JJ, van Genderen PJ, Lindemans J, van Vliet HH: Erythromelalgic, thrombotic Natural history and diagnostic differentiation from Ph-negative essential thrombo-
and hemorrhagic manifestations in 50 cases of thrombocythemia. Leuk Lymphoma 22 cythemia. Ann Hematol 83:504, 2004.
Suppl 1:47, 1996. 62. Godfrey AL, Chen E, Pagano F, et al: JAK2V617F homozygosity arises commonly and
33. Patel RK, Lea NC, Heneghan MA, et al: Prevalence of the activating JAK2 tyrosine recurrently in PV and ET, but PV is characterized by expansion of a dominant homozy-
kinase mutation V617F in the Budd-Chiari syndrome. Gastroenterology 130:2031, gous subclone. Blood 120:2704, 2012.
2006. 63. Godfrey AL, Chen E, Pagano F, et al: Clonal analyses reveal associations of JAK2V617F
34. Passamonti F, Rumi E, Arcaini L, et al: Prognostic factors for thrombosis, myelofibrosis, homozygosity with hematologic features, age and gender in polycythemia vera and
and leukemia in essential thrombocythemia: A study of 605 patients. Haematologica essential thrombocythemia. Haematologica 98:718, 2013.
93:1645, 2008. 64. Olthof SG, Fatrai S, Drayer AL, et al: Downregulation of signal transducer and activa-
35. Campbell PJ, MacLean C, Beer PA, et al: Correlation of blood counts with vascular tor of transcription 5 (STAT5) in CD34+ cells promotes megakaryocytic development,
complications in essential thrombocythemia: Analysis of the prospective PT1 cohort. whereas activation of STAT5 drives erythropoiesis. Stem Cells 26:1732, 2008.
Blood 120:1409, 2012. 65. Li J, Kent DG, Godfrey AL, et al: JAK2V617F homozygosity drives a phenotypic switch
36. Dahabreh IJ, Zoi K, Giannouli S, et al: Is JAK2 V617F mutation more than a diagnostic in myeloproliferative neoplasms, but is insufficient to sustain disease. Blood 123:3139,
index? A meta-analysis of clinical outcomes in essential thrombocythemia. Leuk Res 2014.
33:67, 2009. 66. Chen E, Beer PA, Godfrey AL, et al: Distinct clinical phenotypes associated with
37. Lussana F, Caberlon S, Pagani C, et al: Association of V617F Jak2 mutation with the risk JAK2V617F reflect differential STAT1 signaling. Cancer Cell 18:524, 2010.
of thrombosis among patients with essential thrombocythaemia or idiopathic myelofi- 67. Plo I, Nakatake M, Malivert L, et al: JAK2 stimulates homologous recombination and
brosis: A systematic review. Thromb Res 124:409, 2009. genetic instability: Potential implication in the heterogeneity of myeloproliferative dis-
38. Campbell PJ, Bareford D, Erber WN, et al: Reticulin accumulation in essential throm- orders. Blood 112:1402, 2008.
bocythemia: Prognostic significance and relationship to therapy. J Clin Oncol 27:2991, 68. Zhao R, Follows GA, Beer PA, et al: Inhibition of the Bcl-xL deamidation pathway in
2009. myeloproliferative disorders. N Engl J Med 359:2778, 2008.
39. Elliott MA, Tefferi A: Thrombosis and haemorrhage in polycythaemia vera and essen- 69. Marty C, Lacout C, Droin N, et al: A role for reactive oxygen species in JAK2 V617F
tial thrombocythaemia. Br J Haematol 128:275, 2005. myeloproliferative neoplasm progression. Leukemia 27:2187, 2013.

Kaushansky_chapter 85_p1307-1318.indd 1316 9/21/15 11:09 AM